Antibiotic treatment failure

2021 ◽  
Vol 27 (2) ◽  
pp. 175-182
Author(s):  
Sergey P. Alpatov ◽  
Nadezhda V. Bogush ◽  
Denis A. Borozdenko ◽  
Natalia M. Buyanova ◽  
Irina V. Ganshina ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Treatment Failure ◽  
Practical Interest ◽  
Clinical Trial Data ◽  
Trial Data ◽  
International Drug Monitoring ◽  
The Past ◽  
Scientific Papers ◽  
Antibiotic Failure ◽  
Global Population

This review presents information on cases of antibiotic failure (insufficient effect) in the global population over the past three years. We analyzed scientific papers, clinical trial data, and the WHO Program for International Drug Monitoring (VigiBase) data from 2018 to 2020. The values of global success and safety rates of antibacterial drugs for medical use are presented. The findings may be of practical interest to physicians, researchers, developers, and healthcare regulators.

scholarly journals Targeting Beta Amyloid: A Clinical Review of Immunotherapeutic Approaches in Alzheimer's Disease

2012 ◽  
Vol 2012 ◽  
pp. 1-14 ◽  
Author(s):  
Kasia Lobello ◽  
J. Michael Ryan ◽  
Enchi Liu ◽  
Gregory Rippon ◽  
Ronald Black
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trial ◽  
Clinical Review ◽  
Clinical Trial Data ◽  
Beta Amyloid ◽  
Trial Data ◽  
Significant Progress ◽  
Amyloid A ◽  
The Past

As the societal and economic burdens of Alzheimer's disease (AD) continue to mount, so does the need for therapies that slow the progression of the illness. Beta amyloid has long been recognized as the pathologic hallmark of AD, and the past decade has seen significant progress in the development of various immunotherapeutic approaches targeting beta amyloid. This paper reviews active and passive approaches aimed at beta amyloid, with a focus on clinical trial data.

scholarly journals Cannabinoids for the Treatment of Pain: An Update on Recent Clinical Trials

2005 ◽  
Vol 10 (suppl a) ◽  
pp. 27A-30A ◽  
Author(s):  
Mark Ware ◽  
Pierre Beaulieu
Keyword(s):  
Clinical Trial ◽  
Chronic Pain ◽  
Pain Management ◽  
Considerable Increase ◽  
Clinical Trial Data ◽  
Trial Data ◽  
Clinical Use ◽  
The Past ◽  
Pain Syndromes ◽  
Recent Clinical Trial

Over the past five years, there has been a considerable increase in clinical research on cannabinoid use for a range of pain syndromes. Cannabinoid products are becoming available for research and clinical use, and pharmaceutical industry interest in the potential for cannabinoids in therapeutics is also gaining momentum. The present article summarizes recent clinical trial data in the field of pain management and suggests that the potential for cannabinoid therapy for chronic pain states is encouraging. Clinicians working in pain management should be aware of the options becoming available from the cannabinoid class of medications.

Frailty modelling for multitype recurrent events in clinical trials

2018 ◽  
Vol 19 (2) ◽  
pp. 140-156
Author(s):  
Paul M Brown ◽  
Justin A Ezekowitz
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
Data Structure ◽  
Recurrent Events ◽  
Clinical Trial Data ◽  
Trial Data ◽  
Recurrent Event ◽  
Review Of The Literature ◽  
Survival Times ◽  
The Past

Recurrent event outcomes are ubiquitous among clinical trial data which encourages a conventional approach to analysis. Yet a common feature of these data has received less attention, that is, survival times often comprise multiple types of events that may imply a disparity in cost and disease severity. Typically, we neglect this feature of the data by combining event-types or analyzing each type separately, thus ignoring any interdependence among them. This practice may reflect a dearth of readily available methods and software that more appropriately acknowledge the true data structure. We provide a review of the literature on multitype recurrent events and frailty modelling which reflects a renewed interest in the topic over the past decade and the emergence of software for estimation. Thus, a review of available methods seems timely, if not overdue.

Clinical Trial Data Management Software: A Review of the Technical Features

2019 ◽  
Vol 14 (3) ◽  
pp. 160-172 ◽  
Author(s):  
Aynaz Nourani ◽  
Haleh Ayatollahi ◽  
Masoud Solaymani Dodaran
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
Data Management ◽  
Clinical Data ◽  
Clinical Trial Data ◽  
Trial Data ◽  
Data Management System ◽  
Management Systems ◽  
Data Management Systems ◽  
Technical Features

Background:Data management is an important, complex and multidimensional process in clinical trials. The execution of this process is very difficult and expensive without the use of information technology. A clinical data management system is software that is vastly used for managing the data generated in clinical trials. The objective of this study was to review the technical features of clinical trial data management systems.Methods:Related articles were identified by searching databases, such as Web of Science, Scopus, Science Direct, ProQuest, Ovid and PubMed. All of the research papers related to clinical data management systems which were published between 2007 and 2017 (n=19) were included in the study.Results:Most of the clinical data management systems were web-based systems developed based on the needs of a specific clinical trial in the shortest possible time. The SQL Server and MySQL databases were used in the development of the systems. These systems did not fully support the process of clinical data management. In addition, most of the systems lacked flexibility and extensibility for system development.Conclusion:It seems that most of the systems used in the research centers were weak in terms of supporting the process of data management and managing clinical trial's workflow. Therefore, more attention should be paid to design a more complete, usable, and high quality data management system for clinical trials. More studies are suggested to identify the features of the successful systems used in clinical trials.

Sign in / Sign up

Export Citation Format

Share Document